Clinico-statistical Analysis of 90 Cases of Salivary Gland Tumors

• Published in: Journal of Japanese Society of Oral Oncology Vol. 11; no. 1; pp. 1 - 10
• Main Authors: Sugimura, Masahito, Kirita, Tadaaki, Ohgi, Kazuhiko, Imai, Yuuichirou, Shimooka, Hisashi, Yamanaka, Yasutsugu, Yamamoto, Kazuhiko
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Oral Oncology 1999
• Subjects: clinicopathological study; clinicostatisical analysis; prognosis; salivary gland tumor
• ISSN: 0915-5988; 1884-4995; 1884-4995
• DOI: 10.5843/jsot.11.1

Ninety cases of salivary gland tumors pathologically diagnosed at the Department of Oral and Maxillof acial Surgery, Nara Medical University between October 1981 and June 1997 were clinicostatistically analyzed. The results were as follows: 1. The subjects were 46 male and 44 female patients. 2. Their mean age was 45.1 years for benign tumor and 56.4 years for malignant tumor. The mean age for the benign tumor was similar in both sexes. Males were about 25 years older than females for malignant tumors. 3. Histologically, 72 benign tumors were composed of 61 pleomorphic adenomas, 9 Warthin tumors, 1 myoepithelioma, and 1 cystic lymphangioma. The 18 cases of malignant tumors were composed of 12 adenoid cystic carcinomas, 2 mucoepidermoid car cinomas, 2 basal cell carcinomas, 1 squamous cell carcinoma, and 1 carcinoma in pleomorphic adenoma. 4. The primary tumor sites were the major salivary gland in 36 cases and the minor salivary gland in 54 cases. The most common primary site was the parotid gland for the major salivary gland in 25 cases and the palate for the minor salivary gland in 37 cases. 5. Painless swelling was a characteristic symptom found in all cases of benign tumors. The first clinical findings of malignant tumors were mixed symptoms of pain and others in addition to swelling. 6. Surgical treatment was performed for all benign tumors. For malignant tumors, 4 cases were treated with surgery alone and 11 cases with radiation and/or chemotherapy in addition to surgery. 7. There was no recurrence in any benign tumor case. These cases demonstrated favorable prognoses. The 5-year and 10-year cumulative survival rates were 55.0% in all cases, 100% for the stage I and II group, 41.6% for stage III and IV group, 46.7% for N (1-3) group, and 75.0% for N (0) group, respectively.